<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82229">
  <stage>Registered</stage>
  <submitdate>21/08/2007</submitdate>
  <approvaldate>31/08/2007</approvaldate>
  <actrnumber>ACTRN12607000442404</actrnumber>
  <trial_identification>
    <studytitle>Pharmacokinetics of Azithromycin in pregnancy</studytitle>
    <scientifictitle>Measurement of the pharmacokinetic parameters of Azithromycin in pregnant women to evaluate its potential use in preventing malaria in this population.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Azihromycin 1.5g daily for two days in combination with with either:
1) Chloroquine 10mg/kg daily for three days -or-
2) Sulphadoxine/Pyrimethamine (SP) 25mg/1.25mg per kg as a single dose on the first day</interventions>
    <comparator>The pharmacokinetic disposition of azithromycin will be compared between the group that receives chloroquine and the group receiving sulpfadoxine/pyrimethamine.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Define the pharmacokinetic disposition of Azithromycin in Pregnancy</outcome>
      <timepoint>The amount of azithromycin will be measured from blood taken at 16 time points within a 2 week period. These are 1, 2, 3, 6, 9, 12, 18, 24, 32, 40, 48 hours during the first two days, then again at 3, 4, 5, 7,10 and 14 days.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Examine whether drug-interactions may affect pharmacokinetic disposition when chloroquine or SP are co-administered with azithromycin.</outcome>
      <timepoint>The amount of azithromycin will be measured from blood taken at 16 time points within a 2 week period. These are 1, 2, 3, 6, 9, 12, 18, 24, 32, 40, 48 hours during the first two days, then again at 3, 4, 5, 7,10 and 14 days.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To generate preliminary data on treatment efficacy of azithromycin-chloroquine and azithromycin-SP in pregnant women in Papua New Guinea (PNG).</outcome>
      <timepoint>Reappearance of parasitemia or Polymerase Chain Reaction (PCR) positivity over the 42-day monitoring period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pregnancy
Melanesian</inclusivecriteria>
    <inclusiveminage>-2147483648</inclusiveminage>
    <inclusiveminagetype>N/A</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>N/A</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Severe malaria
Severe anaemia
Pregnancy associated complications</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Papua New Guinea</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Tim M.E. Davis</primarysponsorname>
    <primarysponsoraddress>University of Western Australia
School of Medicine and Pharmacology
Fremantle Hospital
P.O. Box 480 Fremantle
Western Australia 6959</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Ivo Muller</sponsorname>
      <sponsoraddress>PO BOX 60,
Goroka, EHP 411</sponsoraddress>
      <sponsorcountry>Papua New Guinea</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>12/07/2007</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Tim Davis</name>
      <address>University of Western Australia
School of Medicine and Pharmacology
Fremantle Hospital
P.O. Box 480 Fremantle
Western Australia 6959</address>
      <phone>9431 3229</phone>
      <fax />
      <email>tim.davis@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Tim Davis</name>
      <address>University of Western Australia
School of Medicine and Pharmacology
Fremantle Hospital
P.O. Box 480 Fremantle
Western Australia 6959</address>
      <phone>9431 3229</phone>
      <fax />
      <email>tim.davis@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>